Affixus Natural Nail System Humeral Nail PMCF
Launched by ZIMMER BIOMET · Aug 20, 2021
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
The Affixus Natural Nail System Humeral Nail clinical trial is studying a special implant used to treat fractures in the upper arm (humerus). The goal is to confirm that this implant is safe and effective for patients who need surgery for their humeral fractures. They are currently looking for participants who are 18 years or older and have specific types of arm fractures that require a surgical procedure using the Affixus Natural Nail System. To join the study, patients need to be able to follow the doctor's instructions and complete the required follow-up visits after surgery.
If you decide to participate, you will receive the Affixus Natural Nail implant and be monitored to see how well it works and how safe it is for you. It’s important to note that some individuals may not be eligible to participate, such as those with certain medical conditions or previous infections. The study has been approved by a group that ensures the safety and rights of participants, so your well-being is a priority throughout the process.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients 18 years or older and skeletally mature.
- • Patient must have either a proximal humeral fracture or humeral shaft fracture requiring surgical intervention and be eligible for fixation by intramedullary nailing.
- • Patient has been or is scheduled to be treated with the Affixus Natural Nail System Humeral Nail.
- • Patient must be able and willing to complete the protocol required follow-up.
- • Patient must have a signed Institutional Review Board/Ethics Committee approved informed consent. (An Institutional Review Board/Ethics Committee is group that has been formally designated to review and monitor medical research involving human subjects.)
- • Patients capable of understanding the surgeon's explanations and following his instructions, able and willing to participate in the follow-up program and who gave consent to take part in the study.
- Exclusion Criteria:
- • Distal fracture involving the olecranon fossa.
- • Bone shaft having excessive bow or deformity.
- • A medullary canal obliterated by a previous fracture or tumor.
- • Active or previous infection.
- • Skeletally immature patients.
- • All concomitant diseases that can impair the functioning and the success of the implant.
- • Patients with mental or neurologic conditions who are unwilling or incapable of giving proper informed consent and following postoperative care instructions.
- • Patient is a vulnerable subject (prisoner, mentally incompetent or unable to understand what participation to the study entails, a known alcohol or drug abuser, anticipated to be non-compliant).
- • Patient known to be pregnant or breast feeding.
- • Likely problems with maintaining follow-up program (e.g. patient with no fixed address, long distance, plans to move during course of study).
- • Patients who have any condition that would in the judgment of the investigator place the patient at undue risk or interfere with the study.
- • Not expected to survive the duration of the follow-up program.
About Zimmer Biomet
Zimmer Biomet is a leading global medical technology company specializing in the design, development, and manufacturing of innovative orthopedic and surgical products. With a commitment to enhancing patient outcomes, Zimmer Biomet focuses on advancing musculoskeletal health through a broad range of solutions, including joint reconstruction, surgical instrumentation, and dental implants. The company emphasizes research and development, conducting numerous clinical trials to evaluate the safety and effectiveness of its products, while fostering collaboration with healthcare professionals to address the evolving needs of patients and providers alike.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
San Antonio, Texas, United States
Weston, Florida, United States
Barcelona, , Spain
Barcelona, , Spain
Leuven, , Belgium
Frauenfeld, Thurgau, Switzerland
Patients applied
Trial Officials
Hassan Achakri, Ph.D.
Study Director
Director Clinical Affairs
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials